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ABSTRACT 
The aim of this study was to determine whether histone acetylation 
regulates tumor-suppressive microRNA (miRNA) in esophageal squamous 
cell carcinoma (ESCC) and to identify genes which are regulated by the 
miRNA(s).  
We identified a miRNA that was highly upregulated in an ESCC cell line by 
CHAP31, one of the histone deacetylase inhibitors (HDACIs), using a miRNA 
array analysis. miR-375 was strongly upregulated by CHAP31 treatment in 
an ESCC cell line. The expression level of the most upregulated miRNA, 
miR-375 was analyzed by quantitative real-time PCR in human ESCC 
specimens. The tumor suppressive function of miR-375 was revealed by 
restoration of miR-375 in ESCC cell lines. We carried out a microarray 
analysis to identify target genes of miR-375. The mRNA and protein 
expression levels of these genes were verified in ESCC clinical specimens. 
LDHB and AEG-1/MTDH were detected as miR-375-targeted genes.  The 
restoration of miR-375 suppressed the expression of LDHB and 
AEG-1/MTDH. The ESCC clinical specimens exhibited a high level of LDHB 
expression at both the mRNA and protein levels. A loss-of-function assay 
using a siRNA analysis was performed to examine the oncogenic function of 
the gene. Knockdown of LDHB by RNAi showed a tumor suppressive 
function in the ESCC cells. The correlation between the gene expression and 
clinicopathological features was investigated by immunohistochemistry for 
94 cases of ESCC. The positive staining of LDHB correlated significantly 
with lymph node metastasis and the tumor stage. It also had a tendency to 
be associated with a poor prognosis.  
Our results indicate that HDACIs upregulate miRNAs, at least some of 
which act as tumor suppressors. LDHB, which is regulated by the tumor 
suppressive miR-375, might therefore act as an oncogene in ESCC. 
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Abstract 
The aim of this study was to clarify the importance of miR-375 expression in 
patients with esophageal squamous cell carcinoma (ESCC) and to examine 
the in vivo antitumor effects of miR-375 in a model of ESCC using a nonviral 
delivery system. 
We estimated the miR-375 and LDHB and AEG-1/MTDH mRNA expression 
of the ESCC tumors from 85 patients. The correlation between the miR-375 
expression and clinicopathological features, including the prognosis, were 
evaluated. The presence of high miR-375 expression was associated with 
lymphatic vessel invasion, while a low expression of miR-375 significantly 
correlated with a poor prognosis for the 85 ESCC patients. We also found 
that there was a significant inverse correlation between the expression of 
miR-375 and that of LDHB. Before the examination of miR-375 in the in vivo 
assay, we confirmed that atelocollagen prolonged the accumulation of 
miRNA by using fluorescently-labeled miRNA and an in vivo imaging system 
(IVIS)®. We injected the miR-375/atelocollagen complex or a 
control-miRNA/atelocollagen complex into mice bearing TE2 and T.Tn 
xenografts via subcutaneous injections. The growth of both the TE2 and T.Tn 
tumors in the miR-375 groups was significantly suppressed compared with 
that in the control-miRNA groups. In addition, The LDHB mRNA expression 
of TE2 xenografts was significantly downregulated after miR-375 treatment. 
In conclusion, it might be possible for the level of miR-375 expression to be a 
utilized as a prognostic indicator for ESCC patients. The administration of 
miR-375 using a nonviral delivery might represent a powerful new 
treatment for ESCC. 
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Abstract 
Objective: The aim of this study was to identify alternative compounds to 
tumor-suppressive miR-375 using the Connectivity Map (CMAP) and to validate the 
antitumor effects of the identified drugs in esophageal squamous cell carcinoma (ESCC).   
Methods: Gene profiling of miR-375-treated TE2 and T.Tn cells was applied in order 
to search the CMAP database. Among the compounds identified using the CMAP, we 
focused on eight drugs ((-)-epigallocatechin-3-gallate, metformin, rosiglitazone and so 
on), excluding two drugs among the top 10 compounds. We evaluated whether these 
compounds possess tumor suppressive functions in ESCC.  
Results: A cytotoxicity assay showed the sensitivity of TE2 and T.Tn cells treated with 
the eight compounds was evaluated based on IC 50 values of 42.9 µM - 3.8 mM. A cell 
cycle analysis revealed that the percentage of TE2 and T.Tn cells incubated with six 
compounds in the G0/G1 phase or the G2/M phase increased approximately 40-80%. A 
TUNEL assay showed that the percentages of apoptosis cells treated with almost 
compounds were significantly increased (P<0.05) compared with the control cells. 
Conclusion: The CMAP database is a useful tool for identifying compounds affecting 
the same molecular pathways, particularly products that are difficult to apply via 
practical approaches, such as microRNAs. 
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